0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neurodegenerative Disease Treatment Market Research Report 2024
Published Date: February 2024
|
Report Code: QYRE-Auto-10A5968
Home | Market Reports | Health| Health Foundations & Medical Research
Global Neurodegenerative Disease Treatment Market Insights Forecast to 2028
BUY CHAPTERS

Global Neurodegenerative Disease Treatment Market Research Report 2024

Code: QYRE-Auto-10A5968
Report
February 2024
Pages:89
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Neurodegenerative Disease Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Neurodegenerative Disease Treatment Market

Neurodegenerative Disease Treatment Market

Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
The global Neurodegenerative Disease Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Disease Treatment.

Report Scope

The Neurodegenerative Disease Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurodegenerative Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Neurodegenerative Disease Treatment Market Report

Report Metric Details
Report Name Neurodegenerative Disease Treatment Market
CAGR 5%
Segment by Type
  • Neurotransmitter Agents
  • Neuroprotective Agents
  • Biologics
  • Others
Segment by Application
  • Multiple Sclerosis [MS]
  • Alzheimer’s Disease
  • Parkinson's Disease
  • Acute Migraine
  • Autism
  • Narcolepsy
  • Amyotrophic Lateral Sclerosis [ALS]
  • Attention Deficit Hyperactivity Disorder [ADHD]
  • Spinal Muscular Atrophy
  • Huntington's Disease
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Allergan plc, Bayer AG, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Neurodegenerative Disease Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neurodegenerative Disease Treatment Market report?

Ans: The main players in the Neurodegenerative Disease Treatment Market are Allergan plc, Bayer AG, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Ltd.

What are the Application segmentation covered in the Neurodegenerative Disease Treatment Market report?

Ans: The Applications covered in the Neurodegenerative Disease Treatment Market report are Multiple Sclerosis [MS], Alzheimer’s Disease, Parkinson's Disease, Acute Migraine, Autism, Narcolepsy, Amyotrophic Lateral Sclerosis [ALS], Attention Deficit Hyperactivity Disorder [ADHD], Spinal Muscular Atrophy, Huntington's Disease

What are the Type segmentation covered in the Neurodegenerative Disease Treatment Market report?

Ans: The Types covered in the Neurodegenerative Disease Treatment Market report are Neurotransmitter Agents, Neuroprotective Agents, Biologics, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Neurotransmitter Agents
1.2.3 Neuroprotective Agents
1.2.4 Biologics
1.2.5 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Multiple Sclerosis [MS]
1.3.3 Alzheimer’s Disease
1.3.4 Parkinson's Disease
1.3.5 Acute Migraine
1.3.6 Autism
1.3.7 Narcolepsy
1.3.8 Amyotrophic Lateral Sclerosis [ALS]
1.3.9 Attention Deficit Hyperactivity Disorder [ADHD]
1.3.10 Spinal Muscular Atrophy
1.3.11 Huntington's Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disease Treatment Market Perspective (2019-2030)
2.2 Neurodegenerative Disease Treatment Growth Trends by Region
2.2.1 Global Neurodegenerative Disease Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neurodegenerative Disease Treatment Historic Market Size by Region (2019-2024)
2.2.3 Neurodegenerative Disease Treatment Forecasted Market Size by Region (2025-2030)
2.3 Neurodegenerative Disease Treatment Market Dynamics
2.3.1 Neurodegenerative Disease Treatment Industry Trends
2.3.2 Neurodegenerative Disease Treatment Market Drivers
2.3.3 Neurodegenerative Disease Treatment Market Challenges
2.3.4 Neurodegenerative Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disease Treatment Players by Revenue
3.1.1 Global Top Neurodegenerative Disease Treatment Players by Revenue (2019-2024)
3.1.2 Global Neurodegenerative Disease Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Disease Treatment Revenue
3.4 Global Neurodegenerative Disease Treatment Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Treatment Revenue in 2023
3.5 Neurodegenerative Disease Treatment Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Disease Treatment Product Solution and Service
3.7 Date of Enter into Neurodegenerative Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disease Treatment Breakdown Data by Type
4.1 Global Neurodegenerative Disease Treatment Historic Market Size by Type (2019-2024)
4.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Type (2025-2030)
5 Neurodegenerative Disease Treatment Breakdown Data by Application
5.1 Global Neurodegenerative Disease Treatment Historic Market Size by Application (2019-2024)
5.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neurodegenerative Disease Treatment Market Size (2019-2030)
6.2 North America Neurodegenerative Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neurodegenerative Disease Treatment Market Size by Country (2019-2024)
6.4 North America Neurodegenerative Disease Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Disease Treatment Market Size (2019-2030)
7.2 Europe Neurodegenerative Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neurodegenerative Disease Treatment Market Size by Country (2019-2024)
7.4 Europe Neurodegenerative Disease Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease Treatment Market Size (2019-2030)
8.2 Asia-Pacific Neurodegenerative Disease Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Disease Treatment Market Size (2019-2030)
9.2 Latin America Neurodegenerative Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neurodegenerative Disease Treatment Market Size by Country (2019-2024)
9.4 Latin America Neurodegenerative Disease Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease Treatment Market Size (2019-2030)
10.2 Middle East & Africa Neurodegenerative Disease Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan plc
11.1.1 Allergan plc Company Detail
11.1.2 Allergan plc Business Overview
11.1.3 Allergan plc Neurodegenerative Disease Treatment Introduction
11.1.4 Allergan plc Revenue in Neurodegenerative Disease Treatment Business (2019-2024)
11.1.5 Allergan plc Recent Development
11.2 Bayer AG
11.2.1 Bayer AG Company Detail
11.2.2 Bayer AG Business Overview
11.2.3 Bayer AG Neurodegenerative Disease Treatment Introduction
11.2.4 Bayer AG Revenue in Neurodegenerative Disease Treatment Business (2019-2024)
11.2.5 Bayer AG Recent Development
11.3 F. Hoffmann La-Roche Ltd.
11.3.1 F. Hoffmann La-Roche Ltd. Company Detail
11.3.2 F. Hoffmann La-Roche Ltd. Business Overview
11.3.3 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Introduction
11.3.4 F. Hoffmann La-Roche Ltd. Revenue in Neurodegenerative Disease Treatment Business (2019-2024)
11.3.5 F. Hoffmann La-Roche Ltd. Recent Development
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Detail
11.4.2 GlaxoSmithKline plc Business Overview
11.4.3 GlaxoSmithKline plc Neurodegenerative Disease Treatment Introduction
11.4.4 GlaxoSmithKline plc Revenue in Neurodegenerative Disease Treatment Business (2019-2024)
11.4.5 GlaxoSmithKline plc Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Neurodegenerative Disease Treatment Introduction
11.5.4 Johnson & Johnson Revenue in Neurodegenerative Disease Treatment Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Detail
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Neurodegenerative Disease Treatment Introduction
11.6.4 Merck KGaA Revenue in Neurodegenerative Disease Treatment Business (2019-2024)
11.6.5 Merck KGaA Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Detail
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Neurodegenerative Disease Treatment Introduction
11.7.4 Novartis AG Revenue in Neurodegenerative Disease Treatment Business (2019-2024)
11.7.5 Novartis AG Recent Development
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Detail
11.8.2 Pfizer, Inc. Business Overview
11.8.3 Pfizer, Inc. Neurodegenerative Disease Treatment Introduction
11.8.4 Pfizer, Inc. Revenue in Neurodegenerative Disease Treatment Business (2019-2024)
11.8.5 Pfizer, Inc. Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Neurodegenerative Disease Treatment Introduction
11.9.4 Sanofi Revenue in Neurodegenerative Disease Treatment Business (2019-2024)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disease Treatment Business (2019-2024)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Neurodegenerative Disease Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Neurotransmitter Agents
    Table 3. Key Players of Neuroprotective Agents
    Table 4. Key Players of Biologics
    Table 5. Key Players of Others
    Table 6. Global Neurodegenerative Disease Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Neurodegenerative Disease Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Neurodegenerative Disease Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 9. Global Neurodegenerative Disease Treatment Market Share by Region (2019-2024)
    Table 10. Global Neurodegenerative Disease Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 11. Global Neurodegenerative Disease Treatment Market Share by Region (2025-2030)
    Table 12. Neurodegenerative Disease Treatment Market Trends
    Table 13. Neurodegenerative Disease Treatment Market Drivers
    Table 14. Neurodegenerative Disease Treatment Market Challenges
    Table 15. Neurodegenerative Disease Treatment Market Restraints
    Table 16. Global Neurodegenerative Disease Treatment Revenue by Players (2019-2024) & (US$ Million)
    Table 17. Global Neurodegenerative Disease Treatment Market Share by Players (2019-2024)
    Table 18. Global Top Neurodegenerative Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease Treatment as of 2023)
    Table 19. Ranking of Global Top Neurodegenerative Disease Treatment Companies by Revenue (US$ Million) in 2023
    Table 20. Global 5 Largest Players Market Share by Neurodegenerative Disease Treatment Revenue (CR5 and HHI) & (2019-2024)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Neurodegenerative Disease Treatment Product Solution and Service
    Table 23. Date of Enter into Neurodegenerative Disease Treatment Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Neurodegenerative Disease Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 26. Global Neurodegenerative Disease Treatment Revenue Market Share by Type (2019-2024)
    Table 27. Global Neurodegenerative Disease Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 28. Global Neurodegenerative Disease Treatment Revenue Market Share by Type (2025-2030)
    Table 29. Global Neurodegenerative Disease Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 30. Global Neurodegenerative Disease Treatment Revenue Market Share by Application (2019-2024)
    Table 31. Global Neurodegenerative Disease Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 32. Global Neurodegenerative Disease Treatment Revenue Market Share by Application (2025-2030)
    Table 33. North America Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 34. North America Neurodegenerative Disease Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 35. North America Neurodegenerative Disease Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 36. Europe Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. Europe Neurodegenerative Disease Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 38. Europe Neurodegenerative Disease Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Asia-Pacific Neurodegenerative Disease Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 40. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 41. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2025-2030) & (US$ Million)
    Table 42. Latin America Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 43. Latin America Neurodegenerative Disease Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Neurodegenerative Disease Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 46. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 47. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 48. Allergan plc Company Detail
    Table 49. Allergan plc Business Overview
    Table 50. Allergan plc Neurodegenerative Disease Treatment Product
    Table 51. Allergan plc Revenue in Neurodegenerative Disease Treatment Business (2019-2024) & (US$ Million)
    Table 52. Allergan plc Recent Development
    Table 53. Bayer AG Company Detail
    Table 54. Bayer AG Business Overview
    Table 55. Bayer AG Neurodegenerative Disease Treatment Product
    Table 56. Bayer AG Revenue in Neurodegenerative Disease Treatment Business (2019-2024) & (US$ Million)
    Table 57. Bayer AG Recent Development
    Table 58. F. Hoffmann La-Roche Ltd. Company Detail
    Table 59. F. Hoffmann La-Roche Ltd. Business Overview
    Table 60. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Product
    Table 61. F. Hoffmann La-Roche Ltd. Revenue in Neurodegenerative Disease Treatment Business (2019-2024) & (US$ Million)
    Table 62. F. Hoffmann La-Roche Ltd. Recent Development
    Table 63. GlaxoSmithKline plc Company Detail
    Table 64. GlaxoSmithKline plc Business Overview
    Table 65. GlaxoSmithKline plc Neurodegenerative Disease Treatment Product
    Table 66. GlaxoSmithKline plc Revenue in Neurodegenerative Disease Treatment Business (2019-2024) & (US$ Million)
    Table 67. GlaxoSmithKline plc Recent Development
    Table 68. Johnson & Johnson Company Detail
    Table 69. Johnson & Johnson Business Overview
    Table 70. Johnson & Johnson Neurodegenerative Disease Treatment Product
    Table 71. Johnson & Johnson Revenue in Neurodegenerative Disease Treatment Business (2019-2024) & (US$ Million)
    Table 72. Johnson & Johnson Recent Development
    Table 73. Merck KGaA Company Detail
    Table 74. Merck KGaA Business Overview
    Table 75. Merck KGaA Neurodegenerative Disease Treatment Product
    Table 76. Merck KGaA Revenue in Neurodegenerative Disease Treatment Business (2019-2024) & (US$ Million)
    Table 77. Merck KGaA Recent Development
    Table 78. Novartis AG Company Detail
    Table 79. Novartis AG Business Overview
    Table 80. Novartis AG Neurodegenerative Disease Treatment Product
    Table 81. Novartis AG Revenue in Neurodegenerative Disease Treatment Business (2019-2024) & (US$ Million)
    Table 82. Novartis AG Recent Development
    Table 83. Pfizer, Inc. Company Detail
    Table 84. Pfizer, Inc. Business Overview
    Table 85. Pfizer, Inc. Neurodegenerative Disease Treatment Product
    Table 86. Pfizer, Inc. Revenue in Neurodegenerative Disease Treatment Business (2019-2024) & (US$ Million)
    Table 87. Pfizer, Inc. Recent Development
    Table 88. Sanofi Company Detail
    Table 89. Sanofi Business Overview
    Table 90. Sanofi Neurodegenerative Disease Treatment Product
    Table 91. Sanofi Revenue in Neurodegenerative Disease Treatment Business (2019-2024) & (US$ Million)
    Table 92. Sanofi Recent Development
    Table 93. Teva Pharmaceutical Industries Ltd. Company Detail
    Table 94. Teva Pharmaceutical Industries Ltd. Business Overview
    Table 95. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Product
    Table 96. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disease Treatment Business (2019-2024) & (US$ Million)
    Table 97. Teva Pharmaceutical Industries Ltd. Recent Development
    Table 98. Research Programs/Design for This Report
    Table 99. Key Data Information from Secondary Sources
    Table 100. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neurodegenerative Disease Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Neurodegenerative Disease Treatment Market Share by Type: 2023 VS 2030
    Figure 3. Neurotransmitter Agents Features
    Figure 4. Neuroprotective Agents Features
    Figure 5. Biologics Features
    Figure 6. Others Features
    Figure 7. Global Neurodegenerative Disease Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 8. Global Neurodegenerative Disease Treatment Market Share by Application: 2023 VS 2030
    Figure 9. Multiple Sclerosis [MS] Case Studies
    Figure 10. Alzheimer’s Disease Case Studies
    Figure 11. Parkinson's Disease Case Studies
    Figure 12. Acute Migraine Case Studies
    Figure 13. Autism Case Studies
    Figure 14. Narcolepsy Case Studies
    Figure 15. Amyotrophic Lateral Sclerosis [ALS] Case Studies
    Figure 16. Attention Deficit Hyperactivity Disorder [ADHD] Case Studies
    Figure 17. Spinal Muscular Atrophy Case Studies
    Figure 18. Huntington's Disease Case Studies
    Figure 19. Neurodegenerative Disease Treatment Report Years Considered
    Figure 20. Global Neurodegenerative Disease Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 21. Global Neurodegenerative Disease Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 22. Global Neurodegenerative Disease Treatment Market Share by Region: 2023 VS 2030
    Figure 23. Global Neurodegenerative Disease Treatment Market Share by Players in 2023
    Figure 24. Global Top Neurodegenerative Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease Treatment as of 2023)
    Figure 25. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Treatment Revenue in 2023
    Figure 26. North America Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. North America Neurodegenerative Disease Treatment Market Share by Country (2019-2030)
    Figure 28. United States Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Canada Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Europe Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Europe Neurodegenerative Disease Treatment Market Share by Country (2019-2030)
    Figure 32. Germany Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. France Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. U.K. Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Italy Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Russia Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Nordic Countries Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Asia-Pacific Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Asia-Pacific Neurodegenerative Disease Treatment Market Share by Region (2019-2030)
    Figure 40. China Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Japan Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. South Korea Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Southeast Asia Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. India Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Australia Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Latin America Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Latin America Neurodegenerative Disease Treatment Market Share by Country (2019-2030)
    Figure 48. Mexico Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Brazil Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. Middle East & Africa Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. Middle East & Africa Neurodegenerative Disease Treatment Market Share by Country (2019-2030)
    Figure 52. Turkey Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Saudi Arabia Neurodegenerative Disease Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Allergan plc Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2019-2024)
    Figure 55. Bayer AG Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2019-2024)
    Figure 56. F. Hoffmann La-Roche Ltd. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2019-2024)
    Figure 57. GlaxoSmithKline plc Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2019-2024)
    Figure 58. Johnson & Johnson Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2019-2024)
    Figure 59. Merck KGaA Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2019-2024)
    Figure 60. Novartis AG Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2019-2024)
    Figure 61. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2019-2024)
    Figure 62. Sanofi Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2019-2024)
    Figure 63. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2019-2024)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS